FindTrial
Sign In

To study the expression of IHC marker PD-L1 in Urothelial Carcinoma of Urinary Bladder

Study of PD-L1 expression in Urothelial Carcinoma of Urinary Bladder: A Cross Sectional Study. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/109469
Enrollment
90
Registered
2026-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N33- Bladder disorders in diseases classified elsewhere

Interventions

Intervention1: Nil: Nil

Sponsors

Najeeb Ahmed Memon
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All the histopathologically diagnosed cases of UC of the Urinary Bladder that include: 1. Small, intermediate & large biopsies. 2.Resected specimens (Cystectomy) of Urothelial Carcinoma of the Urinary Bladder.

Exclusion criteria

Exclusion criteria: 1. Benign lesions of the Urinary Bladder. 2. Metastatic lesions. 3. Improperly preserved samples. 4. Inadequate samples/specimens.

Design outcomes

Primary

MeasureTime frame
To study the Immunohistochemical expression of PD-L1 in UC of the Urinary Bladder.Timepoint: Baseline—

Secondary

MeasureTime frame
To study the correlation of clinicopathological features with PD-L1 expression & urine cytology or bladder washing in UC of the Urinary Bladder where ever available.Timepoint: Baseline—

Countries

India

Contacts

Public ContactNajeeb Ahmed Memon

KAHERs JNMC, Belagavi

vdhorigol@gmail.com9823696433

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026